Peptide Profile
Angiotensin (1-7)
The heart-friendly peptide that balances your blood pressure and protects your cardiovascular system
Dose Range
0.5-1 mcg/kg-5-10 mcg/kgmcg
Frequency
Once daily
Route
As directed by healthcare provider
Cycle Length
Ongoing/indefinite
Onset
Moderate (1-2 weeks)
Evidence
Moderate
Compound Profile
Scientific & Efficacy Data
C41H62N12O11
Molecular Formula
899.02 g/mol
Molecular Weight
Approximately 2-6 hours (varies by route of administration)
Half-Life
Varies by route of administration
Bioavailability
25016-41-7
CAS #
123805
PubChem ID ↗
Developed By · 1995
Research Team
Academic Research Institutions
Primary Benefits
Protects heart tissue from damage and inflammation
Helps balance blood pressure naturally
Reduces inflammation throughout the cardiovascular system
Amino Acid Sequence
Sequence not publicly available or proprietaryDosing
How much
do I take?
Timing
Best time to take
Use Angiotensin (1-7) at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.
With food?
Angiotensin (1-7) can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.
If stacking
Angiotensin (1-7) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Cardiovascular health and heart protection
Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Blood pressure management and hypertension
Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from heart-related conditions
Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory support
Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Severe hypotension or uncontrolled low blood pressure
- ×Acute myocardial infarction in early stages
- ×Concurrent use with certain ACE inhibitors without medical supervision
- ×Pregnancy and breastfeeding (insufficient safety data)
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Angiotensin (1-7) use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Angiotensin (1-7) vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Angiotensin (1-7) is not FDA-approved and has no completed human clinical trials, with all safety data limited to animal studies and in vitro mechanistic work. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. No pharmacokinetic data exists defining safe doses, optimal delivery routes, or organ accumulation patterns in humans.
Evidence is limited to rat models of hypertension, in vitro vascular studies, and mechanistic research in isolated tissue preparations. No human safety studies, Phase 1 dose-escalation trials, or pharmacokinetic studies have been completed. Published literature focuses on proof-of-concept animal efficacy rather than comprehensive safety profiles. The only human data consists of theoretical extrapolations from animal physiology.
Common Side Effects
Experienced by some users
Hypotension (Low Blood Pressure)
This effect has a common likelihood of occurring. Within 15-30 minutes of injection
Management: Start with low doses. Lie down during injection. Monitor BP regularly. Drink adequate fluids and salt unless restricted. Report severe dizziness.
Dizziness or Lightheadedness
This effect has a common likelihood of occurring. Immediate to 1-2 hours
Management: Sit or lie down immediately after injection. Rise slowly from lying or sitting position. Stay hydrated. Usually resolves within a few hours.
Injection Site Reactions
This effect has a common likelihood of occurring. Immediately at injection site
Management: Rotate injection sites. Apply ice for 5-10 minutes if desired. Keep site clean. Most resolve within a few hours.
Headache
This effect has a moderate likelihood of occurring. 15 minutes to 2 hours
Management: Stay hydrated. Rest in quiet, dark room. May take over-the-counter pain relievers if approved. Usually mild and temporary.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Angiotensin (1-7)
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Angiotensin (1-7) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓Works synergistically in the RAS system to produce Angiotensin (1-7)
- ✓Blocks negative Angiotensin II receptors while allowing protective pathways
- ✓ACE inhibitor that shifts RAS balance toward protective peptides
With medications
- !NSAIDs (High-Dose) - May reduce effectiveness and increase kidney injury risk
- !Potassium Supplements - Risk of dangerous potassium elevation (hyperkalemia)
- !Certain Diuretics - May compound electrolyte imbalances and blood pressure effects
With supplements
- ✓Multivitamins - Generally safe to take alongside Angiotensin (1-7). Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Moderate human trials
What to Expect
Week 1
What you might notice
- •Your body begins responding immediately
- •Blood vessels start to relax and inflammation decreases
- •You might notice slight improvement in energy or reduced bloating
- •Blood pressure begins adjusting—monitor daily
What's normal
- •Initial response to Angiotensin (1-7) is beginning at the cellular level
- •Different individuals experience Angiotensin (1-7)'s onset at different rates
- •Transient systemic effects from initial Angiotensin (1-7) exposure are common
What's next
- →Maintain consistent Angiotensin (1-7) administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Weeks 2-4
What you might notice
- •Initial protective effects become more noticeable
- •Cardiovascular function improves as the Mas receptor pathway activates more consistently
- •Some people notice improved sleep quality or reduced puffiness
- •Kidney function begins improving if kidney support is a goal
What's normal
- •Angiotensin (1-7) is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Angiotensin (1-7)'s mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Angiotensin (1-7) dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Weeks 4-8
What you might notice
- •Significant cardiovascular improvements appear
- •Blood pressure stabilizes at healthier levels
- •Inflammation markers drop noticeably
- •Energy and exercise tolerance improve
What's normal
- •Angiotensin (1-7) is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Angiotensin (1-7)'s mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Angiotensin (1-7) dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Months 2-3
What you might notice
- •Sustained benefits become established
- •Long-term cardiovascular protection increases
- •Many users report feeling more energetic and healthier overall
- •Kidney protection becomes measurable through improved blood work
What's normal
- •Full therapeutic effects of Angiotensin (1-7) are well-characterized at this point
- •Maintenance of Angiotensin (1-7)'s therapeutic effects is typical
- •Tolerance patterns with Angiotensin (1-7) are generally stable over months
What's next
- →Comprehensive assessment of Angiotensin (1-7) efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Angiotensin (1-7) over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"The joint-local renin-angiotensin system in rheumatoid arthritis and osteoarthritis: mechanistic evidence, disease-specific patterns, and translational perspectives"
Research investigators, 2026
Finding: Ang-(1-7) demonstrated protective effects in joint inflammation by modulating the renin-angiotensin system locally. The peptide's ability to reduce inflammatory markers and protect tissue function extends therapeutic potential beyond cardiovascular conditions.
View Study"Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection"
Research investigators, 2026
Finding: SGLT2 inhibitors combined with RAAS blockade demonstrated superior cardiorenal protection through complementary mechanisms. The Ang-(1-7) protective axis works synergistically with these modern therapies, reducing heart failure hospitalization and slowing kidney disease progression without additional safety concerns.
View Study"Exogenous hydrogen sulfide inhibits the progression of vascular dysfunction and hypertension mediated by the renin-angiotensin system in chronic kidney disease"
Research investigators, 2026
Finding: Ang-(1-7) levels were downregulated in chronic kidney disease, but exogenous H2S administration restored protective Ang-(1-7) pathway function. This restored Mas receptor expression, reduced oxidative stress, and prevented vascular dysfunction while improving hypertension management.
View StudyFrequently Asked Questions